INNATE PHARMA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.12.24	Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Businesswire)
09.12.24	Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma (Businesswire)
06.12.24	Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma (Businesswire)
03.12.24	Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 (Businesswire)
20.11.24	Innate Pharma Releases Its 2025 Financial Calendar (Businesswire)
19.11.24	Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 (Businesswire)
13.11.24	Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results (Businesswire)
08.11.24	Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 (Businesswire)
07.11.24	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates (Businesswire)
29.10.24	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Businesswire)
14.10.24	Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board (Businesswire)
30.09.24	Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 (Businesswire)
23.09.24	Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors (Businesswire)
12.09.24	Innate Pharma Reports First Half 2024 Business Update and Financial Results (Businesswire)
09.09.24	Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Businesswire)
05.09.24	Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update (Businesswire)
04.09.24	Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
01.08.24	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Businesswire)
25.07.24	Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024 (Businesswire)
18.06.24	Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024 (Businesswire)
17.06.24	Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial (Businesswire)
04.06.24	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides (Businesswire)
28.05.24	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Businesswire)
24.05.24	Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting (Businesswire)
23.05.24	Outcome of Innate Pharma’s 2024 Annual General Meeting (Businesswire)
21.05.24	Innate Pharma: Clarification Regarding SAR443579 Designation (Businesswire)
15.05.24	Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress (Businesswire)
14.05.24	Innate Pharma Reports First Quarter 2024 Business Update and Financial Results (Businesswire)
07.05.24	Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update (Businesswire)
15.04.24	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 (Businesswire)
15.04.24	Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients (Businesswire)
10.04.24	Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate (Businesswire)
09.04.24	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Businesswire)
05.04.24	Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F (Businesswire)
21.03.24	Innate Pharma Reports Full Year 2023 Financial Results and Business Update (Businesswire)
19.03.24	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Businesswire)
14.03.24	Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results (Businesswire)
06.03.24	Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 (Businesswire)
06.03.24	Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma (Businesswire)
21.02.24	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Businesswire)
12.01.24	Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 (Businesswire)
04.01.24	Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program (Businesswire)
04.01.24	Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board (Businesswire)
19.12.23	Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi (Businesswire)
11.12.23	Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 (Businesswire)
10.12.23	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 (Businesswire)
27.11.23	Innate Pharma to Host Virtual KOL Event on Lacutamab (Businesswire)
14.11.23	Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update (Businesswire)
07.11.23	Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update (Businesswire)
03.11.23	Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	26.98	1.01 %	K V
Roche Hldg G	249.80	0.97 %	K V
Zurich Insur Gr	538.00	0.94 %	K V
Novartis	87.46	0.85 %	K V
Givaudan	3’950.00	0.84 %	K V
Swisscom	500.00	0.32 %	K V
Sonova Hldg	296.10	0.17 %	K V
Nestle	74.02	0.05 %	K V
Sika	213.20	0.00 %	K V
Geberit	511.80	-0.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu INNATE PHARMA SA

Aktien Top/Flop

Meistgelesene Nachrichten